Event Profile

Go Back

Kevin Chen is the founding partner of BioTrack Capital and has spent over 21 years in healthcare as a scientist, entrepreneur and healthcare investor. Kevin brings with him a deep understanding of healthcare market trends and emerging opportunities backed by a broad network of overseas returnees and the entrepreneur community. Prior to founding BioTrack, Kevin was Healthcare Partner at Sequoia China where he led Sequoia China’s investment in healthcare across different stages and subsectors. Before that he was the Head of Everbright’s first ever healthcare fund, Everbright Healthcare Fund I, a China focused healthcare fund. At Sequoia and Everbright, Mr. Chen led investments in over 20 leading healthcare companies in China including BGI, Betta Pharma, Amcare, Venus Medical, Zai Lab, Yuwell and We-Doctor. Before Everbright, he was President, COO and CFO of ShangPharma, a start-up CRO (Contract Research Organization) company he joined as a co-founder in 2008. During Kevin’s tenure, he grew the business from a small family owned business into second biggest CRO in China. He successfully led the IPO of the company on the NYSE in 2010. Before that, Kevin had spent time at CITIC Capital, at DuPont both in the US and China, and was a research scientist at a San Diego based biotech company: Ligand Pharmaceuticals. Kevin holds an MBA from Kellogg, a master’s degree in Medicinal Chemistry & Biochemistry from Tulane University and a bachelor’s degree in Chemistry from Nanjing University.